Socionext (6526) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
6 Jun, 2025Executive summary
Net sales for FY2025/3 declined 14.8% year-over-year to 188.5 billion yen, mainly due to lower demand in China and the end of special 5G demand.
Operating income dropped 29.6% year-over-year to 25.0 billion yen, with margin down to 13.3%.
Profit attributable to owners of parent decreased 25.0% year-over-year to 19.6 billion yen, with margin at 10.4%.
R&D expenses increased 12.3% to 59.8 billion yen, reflecting investment in advanced technologies and new design wins.
Transformation strategy continued, expanding design wins and strengthening global partnerships.
Financial highlights
Product revenue fell 19.8% year-over-year to 146.6 billion yen; NRE revenue rose 9.1% to 41.0 billion yen.
Cost of sales decreased 23.9%, improving product cost ratio by 3.1 points.
Gross profit was 103.9 billion yen; operating margin declined to 13.3% from 16.1%.
Cash and cash equivalents at year-end were 72.8 billion yen, up 3.1 billion yen; total assets declined to 170.3 billion yen.
Shareholders’ equity ratio improved to 80.5% from 70.1% year-over-year.
Outlook and guidance
FY2026/3 net sales forecasted at 175.0 billion yen, down 7.2% year-over-year; operating income expected to fall 44.0% to 14.0 billion yen.
Profit attributable to owners of parent forecast at 10.5 billion yen, down 46.4%.
Guidance reflects continued weak demand in China, inventory adjustments, and FX assumptions of 130 yen/USD.
1H FY2026/3 to see continued weakness from Chinese telecom, with recovery expected in 2H from new automotive and data center mass production.
Mid-term targets: return to net sales growth in FY2027/3, aiming for mid-teen % CAGR and mid- to high-teen % operating margin (excluding FX impact).
Latest events from Socionext
- Sales rebounded, but profits and margins remain pressured by costs and FX; guidance unchanged.6526
Q3 202630 Jan 2026 - Sales guidance raised but profit outlook cut as margins shrink amid higher costs and weak demand.6526
Q2 202631 Oct 2025 - Sharp profit and sales drop in 1Q FY26/3, but full-year guidance and recovery outlook are maintained.6526
Q1 202631 Jul 2025 - Sales and profit fell, but R&D and NRE revenue rose; treasury stock buyback approved.6526
Q2 202513 Jun 2025 - Net sales fell 14.1% but operating income and R&D investment both increased.6526
Q1 202513 Jun 2025 - Net sales dropped 14.4% and the full-year outlook was cut amid weak China demand.6526
Q3 20255 Jun 2025